A personalised mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.This form of cancer therapy harnesses the ...
Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report) and increased the price target to $75.00 from $0.00. Tyler Van Buren’s rating is based on a careful ...